Herzzentrum Leipzig GmbH — Clinical Trial Site

24 Registered trials

12 Currently recruiting

Organisation

Herzzentrum Leipzig GmbH

Location

Leipzig, Germany

Identifier

ORG-100039704

Address

Struempellstrasse 40a, Probstheida, 04289, Germany

Departments

#1421: Herzzentrum Leipzig Kardiologie
#3223:Kardiologie
7002: Universitätsklinik für Herzchirurgie
Abteilung für Radiologie
Cardiac Surgery
Cardiology Clinic
Helios Health Institute GmbH
Herzzentrum Leipzig GmbH
Internal Medicine/Cardiology
Kardiologie
Kinderkardiologie
Klinik fuer Innere Medizin/Kardiologie
Klinik fuer Kardiologie #2106
Klinik für Herzchirurgie
Klinik für Kardiologie
Leipzig Heart Center
N/A
Pediatric Cardiology
Rhythmologie
Universitätsklinik für Kardiologie
Universitätsklinik für Kardiologie – Helios Stiftungsprofessur
Universitätsklinik für Kardiologie an der Universität Leipzig

Clinical trials at this site (24)

Search interface

AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI)… Recruiting

2024-518195-31-00 acute myocardial infarction 6 2021-09-29
Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting

2025-521670-34-00 Acute coronary syndrome (ST-elevation myocardial infarc 5 2026-03-04
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Effects of continued administration of empagliflozin in patients with heart failure on active SGLT2 inhibitor treatment admitted for acute d… Recruiting

2024-517977-26-00 acute decompensated heart failure 5 2025-11-25
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting

2024-513869-39-00 Obstructive Cardiomyopathy, Hypertrophic 5 2025-06-27
A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus applicatio… Recruiting

2024-511037-35-00 Cyclosporine A is a well known medication and is used t 4 2025-01-31
The Direct Oral Anticoagulation versus Vitamin K Antagonist after Cardiac Surgery (DANCE) Trial Recruiting

2023-504504-28-00 Patients with atrial fibrillation requiring anticoagula 5 2024-10-25
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on… Recruiting

2022-502135-19-00 Calcific Aortic Valve Stenosis 4 2024-07-18
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Recruiting

2022-500319-38-00 Paroxysmal supraventricular tachycardia (PSVT) 4 2024-05-03
Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with… Recruiting

2024-515924-35-00 New-Onset Post-Operative Atrial Fibrillation after CABG 6 2023-01-16
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper… Ended

2023-508670-28-00 Hypertension 5 2024-08-26
PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll… Ended

2024-511321-54-00 intermediate-high-risk acute pulmonary embolism 5 2021-08-04
Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi… Ended

2022-501012-34-00 Pulmonary Arterial Hypertension 5 2020-02-27
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Heart Failure 4 2024-03-13
A study to test whether BI 765845 helps people who have had a heart attack Ended

2022-502788-39-00 acute myocardial infarction 4 2023-11-27
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended

2022-501885-24-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-20
A multi-center study to evaluate the safety, tolerability and efficacy of TIN816 in patients at risk for acute kidney injury following a car… Ended

2024-511621-64-00 Acute kidney injury 4 2023-01-18
Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis … Ended

2024-510869-42-00 aortic stenosis patients with high fibrotic burden 4 2022-02-28
Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary … Ended

2024-512727-36-00 Patients with atrial fibrillation and ST-segment elevat 6 2021-12-21
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Ended

2024-518736-37-00 Risk of stroke by Atrial Fibrillation 6 2018-01-12